TrialDermatologic therapy2022

Efficacy and safety of omalizumab in Chinese patients with anti-histamine refractory chronic spontaneous urticaria.

Weiru Yuan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.